Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02497521 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The German ADPKD Tolvaptan Treatment Registry

Study acronym: AD(H)PKD
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2025 to Dec 2027
    • Site details revised at 1 of 12 sites
    v21
  2. Re-verified, no change to tracked fieldsv20
  3. Enrollment target: 500 to 2000v19
  4. 3 versions Re-verified since Feb 3, 2021, no change to tracked fieldsv16-v18
  5. Study description expanded, about 6 words
    • Site contacts updated at 10 of 12 sites
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Enrollment target: 200 to 500
    • Site contacts updated at 2 of 12 sites
    v14
  2. Study sites: 8 to 12v13
  3. Study sites: 7 to 8v12
  4. Site details revised at 1 of 7 sitesv11
  5. Study sites: 6 to 7v10
  6. Re-verified, no change to tracked fieldsv9
  7. Study sites: 3 to 6v8
  8. Study sites: 2 to 3v7
  9. Study sites: 1 to 2v6
  10. Study description expanded, about 25 words
    • Study title shortened, about 3 words
    v5
  11. Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Sep 2025 to Nov 2025
    • Study completion date: Sep 2027 to Dec 2027
    • Start date: Oct 2015 to Nov 2015
    • Eligibility criteria expanded, about 6 words
    • Study description expanded, about 492 words
  12. Re-verified, no change to tracked fieldsv3
  13. Enrollment target: 500 to 200v2 Show 7 more changesShow less
    • Primary completion date: Jun 2020 to Sep 2025
    • Start date: Aug 2015 to Oct 2015
    • Primary endpoints: 1 to 3
    • Study completion date: Sep 2027
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: 7 to 8
    • Study title shortened, about 4 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide "real-world" data on treatment management of patients with ADPKD.
Trial Details
NCT Number NCT02497521
Lead Sponsor University of Cologne
Conditions
(from sponsor)		 ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Related terms Polycystic Kidney Diseases, Polycystic Kidney, Autosomal Dominant
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov